UroGen Pharma URGN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.97M+5.7% | $110.75M-35.6% | $90.04M-27.9% | $92.9M-57.8% | $104.03M-20.9% | ||
| $30.31M-67.0% | $9.71M-85.0% | $36.99M-70.3% | $64.05M+203% | $91.86M+182% | ||
| $1.33M+23.3% | $1.35M+25.5% | $1.35M+25.5% | $1.08M+31.2% | $1.08M+30.7% | ||
| $55.41M+182% | $33.08M+62.9% | $19.7M-13.6% | $19.65M+12.8% | $19.64M+38.7% | ||
| $20.92M+176% | $16.46M+78.4% | $8.34M+9.8% | $7.13M-4.2% | $7.59M+4.8% | ||
| $19.53M+50.4% | $14.67M+65.9% | $12.12M-13.7% | $12.06M-1.3% | $12.98M+23.8% | ||
| $237.46M+0.1% | $186.02M-32.6% | $168.55M-42.9% | $196.87M-29.4% | $237.18M+20.5% | ||
| $616K-1.8% | $637K-2.7% | $695K+14.3% | $688K+18.6% | $627K+10.8% | ||
| $7.49M+1,920% | $5.16M+776% | $6.76M+1,727% | $801K+19.0% | $371K-66.2% | ||
| $253.69M+2.5% | $200.46M-29.8% | $185.05M-38.7% | $208.72M-25.9% | $247.62M+23.5% | ||
| $35.35M+16.6% | $27.72M+1.0% | $26.17M+33.0% | $30.96M+30.3% | $30.32M+67.0% | ||
| $9.84M+41.2% | $13.52M+27.9% | $11.11M+23.1% | $11.65M+70.0% | $6.97M+39.8% | ||
| $589K-7.1% | $481K-38.7% | $429K-48.0% | $668K-16.1% | $634K-18.6% | ||
| $1.33M— | $1.27M— | $1.16M— | —— | —— | ||
| $15.39M+10.2% | $15.28M+14.2% | $15.16M+18.7% | $14.57M+15.6% | $13.97M+12.4% | ||
| $50.64M+20.6% | $46.42M+1.0% | $42.24M+28.8% | $47.55M+38.9% | $42M+59.5% | ||
| $189.53M+55.2% | $122.21M+0.4% | $122.11M+0.3% | $122.51M+25.2% | $122.11M+25.1% | ||
| $4.49M— | $4.75M— | $4.73M— | —— | —— | ||
| $3.07M+383% | $3.13M+121% | $3.1M+199% | $1.22M-0.1% | $637K-55.0% | ||
| $3.16M— | $3.48M— | $3.57M— | —— | —— | ||
| $377.94M+28.5% | $305.93M+3.9% | $300.45M+8.7% | $302.09M+20.1% | $294.08M+22.2% | ||
| $134K+6.3% | $133K+15.7% | $128K+11.3% | $126K+12.5% | $126K+27.3% | ||
| $858.9M+6.9% | $854.09M+7.1% | $817.79M+3.0% | $806.5M+4.0% | $803.47M+19.7% | ||
| -$983.29M-15.7% | -$959.72M-19.0% | -$933.35M-21.4% | -$900.01M-20.8% | -$850.07M-19.5% | ||
| $8K-42.9% | $19K-66.1% | $23K-90.3% | $6K+119% | $14K+138% | ||
| -$124.25M-167% | -$105.47M-1,098% | -$115.41M-552% | -$93.38M-408% | -$46.46M-15.8% | ||
| $253.69M+2.5% | $200.46M-29.8% | $185.05M-38.7% | $208.72M-25.9% | $247.62M+23.5% | ||
| $30.31M-67.0% | $9.71M-85.0% | $36.99M-70.3% | $64.05M+203% | $91.86M+182% | ||
| $7.49M+1,920% | $5.16M+776% | $6.76M+1,727% | $801K+19.0% | $371K-66.2% | ||
| $7.49M+1,920% | $5.16M+776% | $6.76M+1,727% | $801K+19.0% | $371K-66.2% | ||
| $7.49M+1,920% | $5.16M+776% | $6.76M+1,727% | $801K+19.0% | $371K-66.2% | ||
| $9.84M+41.2% | $13.52M+27.9% | $11.11M+23.1% | $11.65M+70.0% | $6.97M+39.8% | ||
| $35.35M+16.6% | $27.72M+1.0% | $26.17M+33.0% | $30.96M+30.3% | $30.32M+67.0% | ||
| $9.84M+41.2% | $13.52M+27.9% | $11.11M+23.1% | $11.65M+70.0% | $6.97M+39.8% | ||
| $5.45M+15.7% | $5.19M-34.8% | $4.96M+21.7% | $4.94M+36.5% | $4.71M+47.4% | ||
| $3.9M+3.0% | $3.9M+3.0% | $3.79M+18.7% | $3.79M+18.7% | $3.79M+18.7% | ||
| $197.09M+56.0% | $130.09M+3.7% | $129.94M+5.9% | $127.47M+28.7% | $126.36M+27.6% | ||
| $858.9M+6.9% | $854.09M+7.1% | $817.79M+3.0% | $806.5M+4.0% | $803.47M+19.7% | ||
| $134K+6.3% | $133K+15.7% | $128K+11.3% | $126K+12.5% | $126K+27.3% | ||
| $1.33M— | $1.27M— | $1.16M— | —— | —— | ||
| $5.65M— | $6.12M— | $6.24M— | —— | —— | ||
| $128.23M+4.0% | $127.28M+4.9% | $126.07M+6.4% | $124.83M+7.7% | $123.34M+9.2% | ||
| $177K+0.6% | $177K+0.6% | $177K+1.1% | $177K+1.1% | $176K-22.1% | ||
| $7.94M— | $8.46M— | $8.49M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's total assets?
- UroGen Pharma (URGN) holds $253.7M in total assets, up 2.5% year over year.
- How much debt does UroGen Pharma have?
- UroGen Pharma carries $197.1M in total debt against -$124.3M of shareholders' equity, a debt-to-equity ratio of 4.81.
- How much cash does UroGen Pharma have?
- UroGen Pharma holds $110.0M in cash and equivalents.
- Can UroGen Pharma cover its short-term obligations?
- Its current ratio is 4.69 — current assets exceed current liabilities.
- Where does UroGen Pharma's balance sheet data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
